Tech titans are hacking their bodies for a longer life: is there science behind their methods? Influencers and ultra-rich people looking to extend their lifespan are trading tips and tricks on how to eke out extra years. By Chris Stokel-Walker

Tech titans are hacking their bodies for a longer life: is there science behind their methods? Influencers and ultra-rich people looking to extend their lifespan are trading tips and tricks on how to eke out extra years. By Chris Stokel-Walker https://www.nature.com/articles/d41586-026-01884-z In 2019, entrepreneur Bryan Johnson began to experiment on himself by taking daily injections of rapamycin. This immunosuppressant drug is typically used to prevent organ rejection after transplants, but the 48-year-old technology entrepreneur and venture capitalist had a different goal — to extend his life.

Precise genome editing of human embryos triggers praise and alarm The ‘base editing’ technique that researchers used is far from ready for the clinic, but critics worry that it will spur a rush to commercialize the approach. By Mohana Basu, Edward Chen & Heidi Ledford

https://www.nature.com/articles/d41586-026-01827-8?utm_source=Live+Audience&utm_campaign=5363efeb1f-nature-briefing-daily-20260608&utm_medium=email&utm_term=0_-33f35e09ea-50432164 Researchers say that they have used a precise genome-editing technique called base editing to alter the genome of human embryos. The announcement has prompted excitement and caution from scientists and bioethicists. Many say that the work is an impressive step towards clinicians being able to fix disease-causing mutations in embryos. But others worry that the technology could be used to try to create embryos with traits such as superior intelligence.

Advances in patient-derived brain organoid models and emerging ethical questions eBioMedicine ++...

Advances in patient-derived brain organoid models and emerging ethical questions eBioMedicine https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(26)00220-3/fulltext Jun 2026 Volume 128 https://www.thelancet.com/journals/ebiom/issue/vol128nonull/PIIS2352-3964(26)X2004-7

Editorial p649 The promise and perils of AI in oncology The Lancet Oncology +...

Editorial p649 The promise and perils of AI in oncology The Lancet Oncology https://www.thelancet.com/journals/lanonc/issue/vol27no6/PIIS1470-2045(26)X2005-8

Editorial p463 Clean Air Day: breathe locally, plan globally The Lancet Respiratory Medicine +...

Editorial p463 Clean Air Day: breathe locally, plan globally The Lancet Respiratory Medicine https://www.thelancet.com/journals/lanres/issue/vol14no6/PIIS2213-2600(26)X2005-7

Editorial Eastern Europe's alcohol-related liver disease crisis is preventable The Lancet Regional Health – Europe – +...

Editorial Eastern Europe's alcohol-related liver disease crisis is preventable The Lancet Regional Health – Europe https://www.thelancet.com/journals/lanepe/issue/vol65nonull/PIIS2666-7762(26)X2002-6

Editorial Primary care is essential to disability inclusion The Lancet Primary Care ++... +

Chemical adherence testing-guided intervention versus standard of care in patients with hypertension who are non-adherent to antihypertensive treatment in the UK (OUTREACH): a multicentre, randomised controlled trial Maciej Tomaszewski, MDa,b Send email to maciej.tomaszewski@manchester.ac.uk ∙ Pankaj Gupta, MDc,d,e ∙ Prof Philip Chowienczyk, BScf ∙ Baptiste Leurent, PhDg ∙ Shadi Hames-Fathi, PhDa ∙ Luana Lenzi, PhDh ∙ et al. https://www.thelancet.com/journals/lanprc/article/PIIS3050-5143(26)00049-X/fulltext?dgcid=raven_jbs_etoc_feature_lanprc Editorial Primary care is essential to disability inclusion The Lancet Primary Care https://www.thelancet.com/journals/lanprc/issue/vol2no5/PIIS3050-5143(26)X2005-2 Association between antihypertensive treatment and hospitalisation or death due to falls according to sex, ethnicity, and social deprivation status: an observational cohort study in English primary care electronic health-care records Florien S van Royen, MD PhDa Send email to f.s.vanroyen-5@umcutrecht.nl ∙ Ariel Wang, PhDb ∙ Prof Geert-Jan Geersing, MD PhDa ∙ Constantinos Koshiaris, PhDc ∙ Subhashisa Swain, PhDb ∙ Prof Amitava Banerjee, MD PhDd,e ∙ et al. https://www.thelancet.com/journals/lanprc/article/PIIS3050-5143(26)00045-2/fulltext?dgcid=raven_jbs_etoc_feature_lanprc

Manufacturing Artificial Retinas in Space to Restore Sight on Earth

https://issnationallab.org/upward/manufacturing-artificial-retinas-in-space-to-restore-sight-on-earth/?utm_source=upward_edm&utm_medium=email&utm_campaign=upward_9.1&utm_content=pr_6-10 Biotech Startup Turns to Space to Manufacture Artificial Retinas LambdaVision’s artificial retinas could one day help restore vision in people with blindness from macular degeneration. However, manufacturing these delicate films on Earth presents challenges. The artificial retinas are made of hundreds of ultra-thin layers of a light-sensitive protein, and gravity-driven forces can cause uneven layering that leads to material waste and limits scalability. To overcome this, the company leveraged the International Space Station (ISS) National Laboratory, where sustained microgravity allows the thin films to form more evenly. Over multiple missions, LambdaVision worked with Commercial Service Provider Space Tango to develop an automated system for manufacturing artificial retinas in space. The result: thin films with improved uniformity, stability, and performance—while using fewer raw materials. This work marks a significant step toward scalable production and highlights how space-based manufacturing can unlock new possibilities for advanced biomaterials on Earth. https://issnationallab.org/press-releases/biotech-startup-turns-to-space-to-manufacture-artificial-retinas-for-treating-blindness/

Treating Metastatic Colorectal Cancer in the Second Line and Beyond: Oral Therapy Edition Authors: Rahul Gosain, MD, MBA; Rohit Gosain, MD; John Strickler, MD; Chiara Cremolini, MD, PhD

https://www.medscape.org/viewarticle/1003002?uac=148436CN&src=mkmcmr_driv_stan_mscpedu_260615-OUS-HONC-1003002-cta

New Pathways in Antithrombotic Therapy Authors: Geoffrey D. Barnes, MD, MSc; Carolyn S. P. Lam, MBBS, PhD; Christian T. Ruff, MD, MPH

https://www.medscape.org/viewarticle/new-pathways-antithrombotic-therapy-2026a1000gtd?page=1

The Evolving Landscape of Sickle Cell Disease Treatment Cristina Ferrario ++++

https://www.medscape.com/viewarticle/evolving-landscape-sickle-cell-disease-treatment-2026a1000k5y STOCKHOLM — The treatment landscape for sickle cell disease (SCD) is evolving rapidly, with new drugs and gene-based therapies offering a realistic prospect of cure. For most patients, however, particularly in low- and middle-income countries (LMICs), access to these innovations remains a major challenge if not a distant dream. The present and future of SCD treatment were explored in depth at an educational session during the European Hematology Association 2026 Congress. Erfan Nur, MD, PhD, clinical hematologist, Amsterdam University Medical Center, chaired the session. Are Artificially Sweetened Beverages Linked to Liver Cancer? Tara Haelle https://www.medscape.com/viewarticle/are-artificially-sweetened-beverages-linked-liver-cancer-2026a1000kav June 16, 2026 Drinking artificially sweetened beverages was not associated with an increased risk for liver cancer, but consumption of sugar-sweetened beverages (SSBs) was linked to two types of liver cancer, a new study found. Surveillance Colonoscopy Offers Limited Value After Age 75 Diana Swift https://www.medscape.com/viewarticle/surveillance-colonoscopy-offers-limited-value-after-age-75-2026a1000kaj June 16, 2026 In adults aged 75 years or older, the risk for death from causes other than colorectal cancer (CRC) greatly exceeded the 10-year risk for diagnosis or CRC-specific death, regardless of previous adenoma diagnosis, a large study of US veterans found. Talquetamab Combinations Show Survival Benefit in r/r Myeloma Randy Dotinga https://www.medscape.com/viewarticle/talquetamab-combinations-show-survival-benefit-r-r-myeloma-2026a1000k6r June 16, 2026 Combinations of the bispecific antibody talquetamab and daratumumab — with or without pomalidomide — outperformed standard therapy in patients with relapsed or refractory (r/r) multiple myeloma, according to an interim analysis of the randomized phase 3 trial MonumenTAL-3.

Encaleret Shows Rapid Response in Autosomal Dominant Hypocalcemia Type 1 Nancy A. Melville June 14, 2026

https://www.medscape.com/viewarticle/encaleret-shows-rapid-response-autosomal-dominant-2026a1000jyu?ecd=wnl_edit_tpal_etid8426964&uac=148436CN&impID=8426964 CHICAGO — Encaleret, an investigational oral drug, shows promise against the difficult-to-treat autosomal dominant hypocalcemia type 1 (ADH1), normalizing calcium, parathyroid (PTH), and phosphate levels, results from a randomized trial show.

Testosterone Prescribing Often Ignores Guidelines Miriam E. Tucker June 14, 2026

https://www.medscape.com/viewarticle/testosterone-prescribing-often-ignores-guidelines-2026a1000jym?ecd=wnl_edit_tpal_etid8426964&uac=148436CN&impID=8426964 CHICAGO — Only a small proportion of men prescribed testosterone therapy received recommended diagnostic testing for androgen deficiency, and many received testosterone therapy despite contraindications, a single-center study showed.

Paclitaxel-loaded poly(glycerol-malate-dodecanedioate) nanoparticles for breast cancer treatment R. Mankamna Kumari, Nikita Sharma, Lacy Loveleen, Nidhi Gupta, Surendra Nimesh Volume 3, Issue 2

https://www.academia.edu/journals/academia-materials-science/articles?source=journal-top-nav Introduction: Polymeric nanoparticles have validated their stance in the field of drug delivery. One such polymer is PGMD, poly (glycerol-malate-dodecanedioate), a novel polymer that has been explored for its potential ability to deliver drugs for the treatment of breast cancer. Materials and methods: PGMD copolymers were synthesized at dodecanedioic acid-to-malic acid molar ratios of 7:3 and 6:4. These formulations were subjected to characterisation using dynamic light scattering (DLS), Field emission scanning electron microscopy (FESEM) and Fourier transform infrared spectroscopy (FTIR). Further, encapsulation efficiency and in vitro release studies were performed. To investigate its anticancer properties, the nanoparticles were implemented for apoptosis analysis using Acridine orange/ethidium bromide (AO/EtBr) and 4′,6-diamidino-2-phenylindole (DAPI) staining, cell migration assay and western-blotting analysis. Results: The 6:4 formulation achieved a superior paclitaxel (PTX) encapsulation efficiency of 97%, compared to 64.5% for the 7:3 variant. Both formed stable, anionic nanocarriers, with the 6:4 nanoparticles exhibiting a hydrodynamic diameter of 188 nm, a polydispersity index of 0.367, and a zeta potential of −17.3 mV. In vitro assays revealed that the PTX-loaded 6:4 PGMD nanoparticles significantly inhibited breast cancer cell migration. Furthermore, the nanoparticles exhibited potent, time-dependent cytotoxicity, achieving a half-maximal inhibitory concentration (IC50) at 48 h in MCF-7 cells, demonstrating significantly enhanced therapeutic efficacy compared to free PTX. Finally, morphological alterations (observed via DAPI and AO/EtBr staining) combined with Caspase-9 overexpression confirmed that this enhanced cytotoxicity is mechanistically driven by the targeted induction of the intrinsic apoptotic pathway. Conclusions: This study validates PGMD-based polymeric nanoparticles as a superior delivery vehicle for paclitaxel in breast cancer treatment. By outperforming the free drug and minimizing toxicity to healthy cells, these nanoparticles represent a highly promising, biocompatible platform for advanced oncological therapy. https://www.academia.edu/2997-2027/3/2/10.20935/AcadMatSci8311

Navigating Cytopenias in Myelofibrosis: Tailoring Personalized Care for Optimal Outcomes Authors: Francesca Palandri, MD; Vikas Gupta, MD, FRCPath; Jennifer O'Sullivan, MD

https://www.medscape.org/viewarticle/navigating-cytopenias-myelofibrosis-tailoring-personalized-2026a10004km?page=1&src=mkmcmr_driv_stan_mscpedu_260616-OUS-HONC-navigating-cytopenias-myelofibrosis-tailoring-personalized-2026a10004km-cta&uac=148436CN

Pediatric Adrenal Insufficiency: Etiology, Diagnosis, and Management by CheckRare Staff| Published on: Jun 11, 2026

Pediatric Adrenal Insufficiency: Etiology, Diagnosis, and Management by CheckRare Staff| Published on: Jun 11, 2026 Mitchell Geffner, MD, Co-Director, Congenital Adrenal Hyperplasia Clinic, and Ron Burkle Chair, Center for Endocrinology, Diabetes, and Metabolism, Children’s Hospital of Los Angeles, discusses the etiology, diagnosis, and management of pediatric adrenocortical insufficiency. https://checkrare.com/pediatric-adrenal-insufficiency-etiology-diagnosis-and-management/

Impact of Vyvgart (Efgartigimod Alfa) Approval for Patients with Seronegative Myasthenia Gravis by Madaline Spencer| Published on: Jun 15, 2026

Impact of Vyvgart (Efgartigimod Alfa) Approval for Patients with Seronegative Myasthenia Gravis by Madaline Spencer| Published on: Jun 15, 2026 Jeff Guptill, MD, Neuromuscular Clinical Development Lead at Argenx, discusses the impact of the Vyvgart (efgartigimod alfa) approval on the myasthenia gravis (MG) community to treat patients with anti-MuSK-Ab positive, anti-LRP4-Ab positive, and/or triple seronegative MG. https://checkrare.com/impact-of-vyvgart-efgartigimod-alfa-approval-for-patients-with-seronegative-myasthenia-gravis/

Safety and Efficacy of Subcutaneous Efgartigimod PH20 in Ocular Myasthenia Gravis by Madaline Spencer| Published on: Jun 16, 2026

Safety and Efficacy of Subcutaneous Efgartigimod PH20 in Ocular Myasthenia Gravis by Madaline Spencer| Published on: Jun 16, 2026 Carolina Barnett-Tapia, MD, Neuromuscular Neurologist and the University of Toronto, discusses the safety and efficacy of subcutaneous efgartigimod PH20 in ocular myasthenia gravis (oMG). https://checkrare.com/safety-and-efficacy-of-subcutaneous-efgartigimod-ph20-in-ocular-myasthenia-gravis/

FDA Expands Approval of Hympavzi (Marstacimab) for Patients With Hemophilia by Madaline Spencer| Published on: Jun 16, 2026

https://checkrare.com/fda-expands-approval-of-hympavzi-marstacimab-for-patients-with-hemophilia/ The US Food and Drug Administration (FDA) has approved an expanded indication for Hympavzi (marstacimab) to include treatment of patients with hemophilia A or B who are 12 years and older with inhibitors, as well as pediatric patients (ages 6 to 11 years) with or without inhibitors.

FDA Public Meeting: FDA-Led Patient-Focused Drug Development Meeting for Nonhealing Chronic Wounds August 25, 2026

https://www.fda.gov/drugs/news-events-human-drugs/fda-public-meeting-fda-led-patient-focused-drug-development-meeting-nonhealing-chronic-wounds?utm_medium=email&utm_source=govdelivery Public Meeting on Patient-Focused Drug Development for Nonhealing Chronic Wounds On August 25, 2026, FDA is hosting a hybrid public meeting on Patient-Focused Drug Development (PFDD) for Nonhealing Chronic Wounds. This meeting will provide FDA and other key stakeholders, including medical product developers, health care providers, and academic researchers, the opportunity to hear directly from patients, patient representatives, and care partners about their experiences with nonhealing chronic wounds, including how the wounds and associated wound care affect their daily life, what matters most to them, their current approaches for managing or treating their nonhealing chronic wounds, and what they consider when determining whether to participate in a clinical trial. There will be three sessions focused on: (1) health effects and daily impacts, (2) current approaches to treatment, and (3) perspectives on clinical trials. For each topic, a brief initial patient panel discussion will begin the dialogue. This will be followed by a facilitated discussion inviting comments from other patient and care partner participants in the audience. Panelists are also welcome to participate in the facilitated discussion. Meeting Logistics and Registration Date: August 25, 2026 Time: 10:00 a.m. – 4:30 p.m. ET Registration: https://www.fda.gov/pfddchronicwounds Location: Attend In Person or Online Virtual: Via Webcast In Person: FDA White Oak Campus, 10903 New Hampshire Ave, Building 31, Room 1503, Silver Spring, MD 20993 Panelists Patients or care partners interested in providing comments as part of the panel discussion are asked to indicate their interest when they register for the meeting. A member of our PFDD Staff will contact them via email. Panelists will be confirmed prior to the meeting and will be invited to a brief one-on-one call with our team to help prepare for their role in the discussion.

Novel analysis identifies unique proliferation gene alterations in diverse cancer patients

https://www.news-medical.net/news/20260615/Novel-analysis-identifies-unique-proliferation-gene-alterations-in-diverse-cancer-patients.aspx New research to be presented today (Monday) at the annual conference of the European Society of Human Genetics shows that a cancer patient's genetic ancestry can have a significant effect both on how their disease progresses and their survival. In the largest study of its kind, researchers examined nearly 1,900 specific genetic changes in tumors in order to measure whether certain mutations were more common in patients with different historic geographic origins.

Mental health diagnostic interviews are less consistent than thought +++

Mental health diagnostic interviews are less consistent than thought Diagnostic interviews are widely used by mental health professionals to identify conditions such as anxiety, bipolar disorder and depression in adults, but new research led by McMaster University shows that the long considered "gold standard" may not be as consistent as previously thought. https://www.news-medical.net/news/20260528/Mental-health-diagnostic-interviews-are-less-consistent-than-thought.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=bipolar_disorder_newsletter_10_june_2026 Massive global analysis examines cognitive development in children of affected parents https://www.news-medical.net/news/20260519/Massive-global-analysis-examines-cognitive-development-in-children-of-affected-parents.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=bipolar_disorder_newsletter_10_june_2026 A new study led by Murdoch University has found that children of parents with severe mental illness are more likely to experience cognitive difficulties. Severe mental illnesses such as schizophrenia, bipolar disorder, and major depressive disorder affect over 247 million people worldwide. Large study uncovers brain network differences in bipolar disorder https://www.news-medical.net/news/20260609/Large-study-uncovers-brain-network-differences-in-bipolar-disorder.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=bipolar_disorder_newsletter_10_june_2026 New research from the Mark and Mary Stevens Neuroimaging and Informatics Institute (Stevens INI) at the Keck School of Medicine of USC has discovered subtle but widespread differences in the brain's communication networks in people with bipolar disorder, offering new insight into how illness severity and treatment may relate to brain wiring.

Sex-dependent depression symptoms reduce healthspan in older adults

https://www.news-medical.net/news/20260615/Sex-dependent-depression-symptoms-reduce-healthspan-in-older-adults.aspx Depression is a serious mental health issue that can rob us of joy - and years of healthy living. While we know that depressive symptoms can cut down the remaining years of disability-free living (or "healthspan") in older adults, it was unclear exactly which symptoms could be the culprit. Researchers from Tohoku University, the Tohoku Medical Megabank Organization, and the National Institute of Biomedical Innovation, Health and Nutrition have found that different patterns of depressive symptoms are associated with disability-free survival in community dwelling older adults, and that these associations differ between men and women.

New mRNA flu vaccine offers broader protection against influenza strains

https://www.news-medical.net/news/20260615/New-mRNA-flu-vaccine-offers-broader-protection-against-influenza-strains.aspx A new study led by researchers at Washington University School of Medicine in St. Louis has found that an investigational mRNA influenza vaccine helps the immune system recognize a wider range of influenza viruses than today's standard flu shot, offering stronger and potentially longer-lasting protection.

Australia’s diphtheria outbreak shows why boosters, antibiotics, and better housing all matter

https://www.news-medical.net/news/20260615/Australiae28099s-diphtheria-outbreak-shows-why-boosters-antibiotics-and-better-housing-all-matter.aspx A 131-case outbreak reveals how a vaccine-preventable disease regained a foothold in the Northern Territory, exposing the urgent need for booster vaccination, rapid treatment, genomic surveillance, and better housing. In a recent study published in the journal Eurosurveillance, a group of researchers investigated the epidemiology, laboratory characteristics, genomic features, and public health response associated with the 2025-2026 diphtheria outbreak in Australia’s Northern Territory.

Stroke still strikes hard: we need more primary prevention The Lancet Regional Health – Americas +...

Stroke still strikes hard: we need more primary prevention The Lancet Regional Health – Americas https://www.thelancet.com/journals/lanam/issue/vol58nonull/PIIS2667-193X(26)X2003-8

The hidden burden of schistosomiasis in women and girls The Lancet Microbe +...

The hidden burden of schistosomiasis in women and girls The Lancet Microbe https://www.thelancet.com/journals/lanmic/issue/vol7no6/PIIS2666-5247(26)X2005-5

For adults with prediabetes, lifestyle intervention lowered risk of developing multiple chronic conditions

For adults with prediabetes, lifestyle intervention lowered risk of developing multiple chronic conditions A clinical trial supported by the National Institutes of Health (NIH) found that adults with prediabetes assigned to a lifestyle intervention had a significantly lower risk of developing multiple chronic health conditions (known as multimorbidity) over time than those assigned to a placebo. This study, which followed participants for over two decades, also found that participants assigned to receive metformin did not experience a statistically significant reduction in multimorbidity risk. The findings, published in JAMA, highlight the lasting benefits of lifestyle programs that may lower risk of the development of chronic conditions. https://www.nih.gov/news-events/news-releases/adults-prediabetes-lifestyle-intervention-lowered-risk-developing-multiple-chronic-conditions

Editorial Putting rural health first in the fuel crisis The Lancet Regional Health – Western Pacific ++...

Efficacy and safety of savolitinib in Chinese patients with locally advanced or metastatic MET exon 14-mutated non-small cell lung cancer: final results of a confirmatory Phase 3b study Yongfeng Yua ∙ Qisen Guob ∙ Yongchang Zhangc ∙ Jian Fangd ∙ Diansheng Zhonge ∙ Baogang Liuf ∙ et al. https://www.thelancet.com/journals/lanwpc/article/PIIS2666-6065(26)00038-6/fulltext?dgcid=hubspot_email_infocusalerts-oncology_feature&utm_campaign=infocusalerts-oncology&utm_medium=email&_hsenc=p2ANqtz-_zwgIxW6EH4LpihWxg6pR1OePwenmJAjsRsbQX22rFf9DcJNUcGvMUWVsspW5IHhm5pjlbdaXTWHxFmLnlwP_leUzKFg&_hsmi=423663681&utm_content=423512653&utm_source=hs_email Editorial Putting rural health first in the fuel crisis The Lancet Regional Health – Western Pacific https://www.thelancet.com/journals/lanwpc/issue/vol69nonull/PIIS2666-6065(26)X2002-8

Preventing the next pandemic using AI-designed vaccines A first-in-human trial shows how computationally designed antigens could help shift vaccines from reactive to future-proof. Written byBree Foster, PhD

https://www.drugdiscoverynews.com/preventing-the-next-pandemic-using-ai-designed-vaccines-17251 For most of human history, infectious diseases were the main causes of morbidity and mortality. Advances in sanitation, antibiotics, vaccines, and public health dramatically shifted that balance, particularly in high-income countries, where life expectancy has increased by nearly 40 years over the past century. Yet the COVID-19 pandemic provided a stark reminder that infectious threats can still reshape societies almost overnight. Between 2019 and 2021 alone, life expectancy in the US fell by more than two years, and recent modelling suggests there is roughly a 50 percent chance of another COVID-scale pandemic occurring within the next 25 years.

Reminder: Lessons from the Regional Partnership Grants Program — What Works for Families Thursday, June 18, 2-2:30 p.m. ET

Reminder: Lessons from the Regional Partnership Grants Program — What Works for Families Thursday, June 18, 2-2:30 p.m. ET https://cffutures-net.zoom.us/webinar/register/WN_p6E_aMx-QWyIYt1ROPaJbQ?utm_source=SAMHSA&utm_campaign=3da5755b92-EMAIL_CAMPAIGN_2026_06_09_03_28_COPY_01&utm_medium=email&utm_term=0_-1586aa3de5-167840245#/registration Feeling overwhelmed by information overload? Looking for ready-to-use resources you can immediately apply to your work? Spend 30 minutes exploring a practical resource that helps systems work together more effectively for families—Lessons from the Regional Partnership Grants Program: What Works for Families. Families affected by substance use often navigate multiple systems with different priorities, timelines, and expectations—all of which make effective collaboration challenging. This session introduces a National Center on Substance Abuse and Child Welfare (NCSACW) brief that summarizes key collaboration strategies identified through 20 years of Regional Partnership Grants (RPG) Program experience. Learn how you can apply the highlighted strategies—such as shared goals, formal structures, integrated services, and data-informed decision-making—in your work. This is not an in-depth training on RPG or collaboration models; instead, it’s a guided overview of a tool you can use and share with your colleagues immediately. Don’t miss this opportunity to explore available resources that can strengthen your work and support collaboration across systems.

Cancer workforce—a global crisis +...

https://www.thelancet.com/commissions-do/cancer-workforce?dgcid=hubspot_email_conferencealerts_asco26_lanoncworkforce26&utm_campaign=conferencealerts&utm_medium=email&_hsenc=p2ANqtz-9xbT6xfej9Arq7AXedqih84Vn3HRMrF53DSQsS1d7U5cI5UBZ6dBTe2v6EaImPv4BcBfukkBbTHKISNuby_55gczLQGw&_hsmi=422717838&utm_content=422717838&utm_source=hs_email Executive summary A sufficiently resourced, multidisciplinary, workforce is essential for delivering cancer care and doing clinically relevant research, as well as being a major barrier to reducing disparities in cancer outcomes between high-income and low-income settings. The Lancet Oncology’s Commission on Cancer workforce—a global crisis provides actionable guidance for strengthening the global cancer workforce with an emphasis on reducing global disparities. The Commission models the current and future global landscape of common cancers and workforce personnel types to better understand the extent of the changing global cancer burden and workforce needs. Focusing on examples from sub-Saharan Africa and Latin America, the authors also examine obstacles to workforce development and retention in low-income and middle-income countries and propose pragmatic actions to address the workforce crisis.

Editorial Making older women more visible in healthy ageing The Lancet Regional Health – Western Pacific +...

Editorial Making older women more visible in healthy ageing The Lancet Regional Health – Western Pacific https://www.thelancet.com/journals/lanwpc/issue/vol70nonull/PIIS2666-6065(26)X2003-X

In many South Asian American families, a child’s autism diagnosis is a secret Cultural norms and health system failures make it difficult for kids to access the care they need +++

https://www.statnews.com/2026/06/15/autism-diagnosis-south-asian-american-families-stigma/ By Ritu GoelJune 15, 2026 Goel is a double board-certified child, adolescent, and adult psychiatrist and founder of MindClaire PC. I’m a pediatrician. I want to prescribe the right AI to my patients Parents and children need updated guidance and evidence-based AI tools for development https://www.statnews.com/2026/06/15/ai-children-screen-time-pediatrician-prescription-guidance/ By Dua HassanJune 15, 2026 Hassan is a physician at Boston Children’s Hospital. FDA approves Sanofi diabetes drug for children with stage 3 diabetes Former CDER head Tracy Beth Høeg had disagreed with staff on approval https://www.statnews.com/2026/06/13/teplizumab-tzield-sanofi-fda-approval-children-stage-3-diabetes/ By Lizzy LawrenceJune 13, 2026 FDA Reporter

How partnership accelerated access to innovative bladder cancer treatment at a community urology practice

https://www.statnews.com/sponsor/2026/05/26/how-partnership-accelerated-access-to-innovative-bladder-cancer-treatment-at-a-community-urology-practice/ By Aleksandar Alchev, MBAMay 26, 2026 This post is sponsored by Johnson & Johnson

Amid confusion over Pfizer’s emergency penicillin program, newborn is diagnosed with preventable syphilis Rise in adult cases and Bicillin shortage set stage for ’never event’

https://www.statnews.com/2026/06/15/pfizer-bicillin-shortage-preventable-congenital-syphilis-surging/?utm_campaign=morning_rounds&utm_medium=email&_hsenc=p2ANqtz-_56UZJHlWa2EG5CiZbTHIjQzKfpD5XD68viLBj_hQX2c3qHZL8muBB5spe4TUBzYNjx99wOvIXSp96J_IpDU2bmDBEyA&_hsmi=423738578&utm_content=423738578&utm_source=hs_email By Eric BoodmanJune 15, 2026 For this story, Boodman obtained email chains between Pfizer and health officials and conducted interviews with 10 state health departments, eight local health agencies, six health system pharmacists, and former and current CDC officials, as well as infectious disease specialists, OB-GYNs, and representatives of Pfizer and Cost Plus Drugs, among other sources. A child born with congenital syphilis could suffer dire consequences: bone deformities, brain damage, blindness, deafness, and more. But that should be a ‘never event’ as public health officials say: A pregnant person can receive an injectable form of penicillin to prevent the infection. Somehow, rates keep going up anyway. Between 2012 and 2024, the U.S. saw an 800% increase in babies born with the disease. And since last year, there’s been a shortage of the drug. Pfizer, the only company that sells it, has an emergency request system for pregnant patients. But public health officials say the program is confusing and that some companies may get preferential treatment. In his latest story, STAT's Eric Boodman illustrates each hurdle that kept one Arizona mother from accessing the medication before delivering her baby, despite multiple attempts on her behalf to obtain the drug. He reviewed email chains between Pfizer and health officials, while also conducting interviews with local health agencies, pharmacists, infectious disease specialists, OB-GYNs, and Mark Cuban.

IMPACT EBC: IMPlementing Advances in Cancer Treatment for Patients With HR+/HER2- Early Breast Cancer - Moving Patient Care Forward +...

IMPACT EBC: IMPlementing Advances in Cancer Treatment for Patients With HR+/HER2- Early Breast Cancer - Moving Patient Care Forward Approximately 30% of patients with early breast cancer (EBC) will eventually develop metastatic disease. In hormone receptor (HR)-positive breast cancer, approximately 50% of recurrences occurs within 5 years of diagnosis. Many factors should be considered when evaluating a patient's risk of recurrence, including HR status, and human epidermal growth factor receptor 2 (HER2) status, nodal involvement, histologic grade, anatomic stage, positive or close margins, proliferate rate, tumor size, and the patient's age and health status. IMPlementing Advances in Cancer Treatment for Patients With HR-Positive, HER2-Negative Early Breast Cancer is a collection of educational programs designed for clinicians to stay up to date on the clinical data that supports decision-making for patients with HR-positive, HER2-negative EBC at risk of recurrence and make an IMPACT on patient outcomes and quality of life. https://www.medscape.org/advances/implementing-advances-cancer-treatment-patients-hr-her2-2025a1000yzz?src=mkmcmr_driv_32025_mscpedu_436313.01_ace_launch&uac=148436CN

Teen Gunshot Victim Develops Delayed Complications Janice Verham, MD May 18, 2026 ++++

https://reference.medscape.com/viewarticle/teen-gunshot-victim-develops-delayed-complications-2026a1000fni?ecd=WNL_casechlg_260614_MSCPREF_etid8418307&uac=148436CN&impID=8418307 Editor's Note: The Case Challenge series includes difficult-to-diagnose conditions, some of which are not frequently encountered by most clinicians, but are nonetheless important to accurately recognize. Test your diagnostic and treatment skills using the following patient scenario and corresponding questions. If you have a case that you would like to suggest for a future Case Challenge, please email us at ccsuggestions@medscape.com with the subject line "Case Challenge Suggestion." We look forward to hearing from yo A Violaceous Retiform Rash With Progressive Lower Extremity Ischemia in a 66-Year-Old Man Margaret Mercante; Rishab Revankar, MD; Shira Lanyi, MD; Gabrielle Schwartzman, MD; Danielle Nelson, MD; Scott Berg, MD; Barrett Zlotoff, MD https://reference.medscape.com/viewarticle/violaceous-retiform-rash-progressive-lower-extremity-2026a1000d6p?ecd=WNL_casechlg_260614_MSCPREF_etid8418307&uac=148436CN&impID=8418307 April 30, 2026 A 66-year-old man with a history of JAK2-positive essential thrombocytosis, polysubstance use disorder, and prior right lower extremity osteomyelitis status post-toe amputation presents with worsening right foot pain, ulceration, and a violaceous rash extending proximally up the lower extremity. The patient reports having progressive pain and discoloration over several weeks. There is no recent history of trauma, new medications, or systemic infectious symptoms. Incidental PSA Elevation in a 69-Year-Old Former Smoker with Hypertension Abdul Baseet Arham, MBBS; Valentina Marulanda-Corzo, MD; Scott T. Tagawa, MD, MS https://reference.medscape.com/viewarticle/incidental-psa-elevation-69-year-old-former-smoker-2026a1000al6?ecd=WNL_casechlg_260614_MSCPREF_etid8418307&uac=148436CN&impID=8418307 April 14, 2026 A 69-year-old man with a history of medically managed hypertension and hyperlipidemia was referred to urology with an incidentally detected prostate-specific antigen (PSA) level of 6.6 ng/mL. The patient reported no voiding or sexual issues and denied constitutional symptoms. The only family history of cancer was lung cancer in his father, who was a smoker. Examination of his prostate revealed no palpable nodules. Vertex Balding and Clitoromegaly in a Muscular 32-Year-Old Woman Lauren G. Yi; Richard Harold Flowers, IV, MD https://reference.medscape.com/viewarticle/vertex-balding-and-clitoromegaly-muscular-32-year-old-woman-2026a1000878?ecd=WNL_casechlg_260614_MSCPREF_etid8418307&uac=148436CN&impID=8418307 March 25, 2026

HER2-Positive Gastroesophageal Adenocarcinoma and Biliary Tract Cancer: Updates and Insights Authors: Haley Ellis, MD; Steven Maron, MD, MSc

https://www.medscape.org/viewarticle/her2-positive-gastroesophageal-adenocarcinoma-and-biliary-2025a1000sr3?page=1&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_260614-OUS-HONC-her2-positive-gastroesophageal-adenocarcinoma-and-biliary-2025a1000sr3-cta

Managing Endometrial Cancer: Unpacking the Data Behind the Latest Immunotherapy Advancements Authors: Ana Oaknin, MD, PhD; Domenica Lorusso, MD, PhD

https://www.medscape.org/viewarticle/managing-endometrial-cancer-unpacking-data-behind-latest-2026a1000bh0?page=1&src=mkmcmr_driv_stan_mscpedu_260614-OUS-HONC-managing-endometrial-cancer-unpacking-data-behind-latest-2026a1000bh0-cta&uac=148436CN

GLP-1 therapy associated with more dizziness and fainting

https://www.news-medical.net/news/20260614/GLP-1-therapy-associated-with-more-dizziness-and-fainting.aspx Northwestern Medicine scientists have identified a safety concern associated with GLP-1 drugs. Using health record data, the research team tracked more than 42,000 adults already taking at least two types of blood pressure medications. After starting GLP-1s, these patients experienced higher rates of dizziness, fainting and other events related to low blood pressure, also known as hypotension.

Eliminating dietary sugar may disrupt gut health and promote inflammation

https://www.news-medical.net/news/20260614/Eliminating-dietary-sugar-may-disrupt-gut-health-and-promote-inflammation.aspx Eliminating sugar from your diet may be more detrimental than previously thought, according to an animal study being presented Saturday at ENDO 2026, the Endocrine Society's annual meeting in Chicago, Ill.

How Gut Fungi and Archaea Influence Human Health

https://www.news-medical.net/health/How-Gut-Fungi-and-Archaea-Influence-Human-Health.aspx The non-bacterial gut microbiome, particularly fungi and archaea, plays an important role in metabolism, immune regulation, and microbial ecosystem stability through complex interactions with bacteria and the host. Emerging research links fungal dysbiosis and methanogenic archaea to obesity, inflammatory disorders, gastrointestinal disease, and potential future microbiome-based therapies. The gut microbiome comprises bacteria, fungi, archaea, viruses, and other microorganisms that influence health and disease. The biological significance of intestinal bacteria is well-established; however, recent advances in sequencing technologies indicate that both the gut mycobiome and archaeome are involved in metabolism, immune regulation, and microbial balance that influence the risk of developing obesity, inflammatory disorders, and diseases of the gastrointestinal tract.1,2,3 Although fungi represent only a small fraction of total gut microbes, they can have disproportionate effects through immune signaling, microbial competition, and interactions with bacteria

How to Stay Motivated to Exercise

https://www.news-medical.net/health/How-to-Stay-Motivated-to-Exercise.aspx Why do some people maintain exercise habits for years while others quit within weeks? Emerging research shows that enjoyment, autonomy, positive emotions, and social support are often more important for long-term adherence than knowing the health benefits alone. Regular physical activity reduces the risk of chronic diseases while improving both physical and psychological health. Despite these established benefits, many individuals struggle to adhere to a regular exercise routine, whereas others are more successful at sustaining long-term exercise habits. Understanding why some people continue exercising while others discontinue is essential for developing effective long-term health interventions. Exercise adherence can be understood not only as compliance with a program, but also as the dynamic alignment between a person's attitudes and exercise behavior.

How Meal Timing Affects Metabolism and Weight Loss

https://www.news-medical.net/health/How-Meal-Timing-Affects-Metabolism-and-Weight-Loss.aspx Meal timing helps regulate hunger, glucose control, lipid metabolism, and energy balance through its alignment with circadian rhythms. Eating earlier and maintaining consistent meal and sleep schedules may support better metabolic health. Meal timing is increasingly recognized as a key determinant of metabolic health, as it influences glucose homeostasis, energy production, and hormonal regulation. Aligning food intake with endogenous circadian rhythms has the potential to improve metabolic outcomes and reduce the risk of obesity, type 2 diabetes, and other cardiometabolic disorders.

Oral GLP-1 drug elecoglipron helps adults lose up to 11.8% body weight

https://www.news-medical.net/news/20260611/Oral-GLP-1-drug-elecoglipron-helps-adults-lose-up-to-11825-body-weight.aspx A once-daily oral small-molecule GLP-1 receptor agonist delivered progressive, dose-dependent weight loss without food or fluid restrictions, supporting larger phase 3 trials for long-term weight management. In a recent study published in The Lancet, a group of researchers evaluated the efficacy, safety, and tolerability of oral non-peptide small-molecule elecoglipron for weight management in adults with obesity or overweight and at least one weight-related health condition without diabetes.

The next steps for chronic kidney disease The Lancet ++...

The next steps for chronic kidney disease The Lancet https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)01183-9/fulltext?dgcid=raven_jbs_etoc_email Jun 13, 2026 Volume 407Number 10546p2345-2472 https://www.thelancet.com/journals/lancet/issue/vol407no10546/PIIS0140-6736(26)X2021-9

Ebola Collection

https://www.thelancet.com/ebola?dgcid=raven_jbs_etoc_feature_ebola26

The Lancet Series on cardiometabolic multiple long-term conditions

https://www.thelancet.com/series-do/cardiometabolic-mltc?dgcid=raven_jbs_etoc_feature_lancetcardiomltc26 Cardiometabolic multiple long-term conditions (multimorbidity), the co-occurrence of interconnected conditions such as type 2 diabetes, cardiovascular disease, and kidney disease, represent a growing global health challenge. Clustering of these conditions is associated with polypharmacy, high rates of morbidity, disproportionate health care utilisation, and premature mortality. Despite rising prevalence in both low- and high-income countries, clinical care and research often remain siloed within single-disease frameworks, resulting in fragmented management and suboptimal outcomes.

Prospective Cutaneous Lymphoma International Prognostic Index Study Jun 8, 2026 | Skin Conditions ▼

Prospective Cutaneous Lymphoma International Prognostic Index Study Jun 8, 2026 | Skin Conditions ▼ Julia Scarisbrick, MD, MBhons, ChB, FRCP, is one of the leaders of the PROCLIPI (Prospective Cutaneous Lymphoma International Prognostic Index) study, a registry of patients with cutaneous T-cell... https://checkrare.com/

Preferences and Perceptions of Acute Seizure Medications by Madaline Spencer| Published on: Jun 12, 2026

Preferences and Perceptions of Acute Seizure Medications by Madaline Spencer| Published on: Jun 12, 2026 Kerrie-Anne Ho, PhD, Patient Preference Lead at UCB, discusses preferences and perceptions of acute seizure medications. https://checkrare.com/preferences-and-perceptions-of-acute-seizure-medications/

Most Read Cancer Science & Oncogenesis +...

https://read.qxmd.com/collection/1133?ecd=wnl_readmost_260612

Current and Future Oral SERD Strategies in the Management of ER-Positive/HER2-Negative MBC: Analyzing the Clinical Data Authors: Komal Jhaveri, MD, FACP, FASCO; Shaheenah Dawood, MD, MPH

https://www.medscape.org/viewarticle/current-and-future-oral-serd-strategies-management-er-2026a100022b?page=1&src=mkm_driv_cust_mscpedu_260612-12153256&uac=148436CN

Ongoing Perspectives in HER2-Mutated Advanced NSCLC: An Expert Viewpoint on the Latest Data Authors: Helena Yu, MD

https://www.medscape.org/viewarticle/ongoing-perspectives-her2-mutated-advanced-nsclc-expert-2026a10001va?page=1&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_260613-OUS-HONC-ongoing-perspectives-her2-mutated-advanced-nsclc-expert-2026a10001va-cta

Advancing Personalized Care for Prostate Cancer: Patient-Centered Solutions for mHSPC and nmCRPC Authors: Alicia K. Morgans, MD, MPH, FASCO; Christian Gratzke, MD; Fred Saad, MD, FRCS, FCAHS; Tony Collier, BEM

https://www.medscape.org/viewarticle/advancing-personalized-care-prostate-cancer-patient-centered-2025a1000uyb?page=1&src=mkmcmr_driv_stan_mscpedu_260613-OUS-HONC-advancing-personalized-care-prostate-cancer-patient-centered-2025a1000uyb-cta&uac=148436CN

Chronic Lymphocytic Leukemia: Data-Driven Updates in First-Line and R/R Disease Authors: Barbara F. Eichhorst, MD; Toby A. Eyre, MD, MBChB, DipMedEd, MRCP, FRCPath; Catherine Coombs, MD; Chan Cheah, MBBS, DMSc

https://www.medscape.org/viewarticle/chronic-lymphocytic-leukemia-data-driven-updates-first-line-2026a1000imb?page=1&src=wnl_tpal_260613_mscpedu&uac=148436CN&impID=8421426

The Only Sleep Study I Can Get Is a PAT Aaron B. Holley, MD +++++

The Only Sleep Study I Can Get Is a PAT Aaron B. Holley, MD https://www.medscape.com/viewarticle/only-sleep-study-i-can-get-pat-2026a1000jab?ecd=wnl_edit_tpal_etid8422209&uac=148436CN&impID=8422209 Twenty years ago, high reimbursement rates for in-lab polysomnograms (PSGs) gave sleep labs a license to print money. Labs proliferated like tags on a viral tweet. Thanks to the American Academy of Sleep Medicine’s (AASM) efforts to ensure everyone has sleep apnea (OSA), the resulting capacity still couldn’t meet the demand. The sleep field was winning, but patients and payors were not. Getting Into a Medical Residency Is Harder Than Ever, Here’s Why June 12, 2026 Every March, thousands of newly minted doctors find out in a single anxious moment — Match Day — whether they have a job. Most do. But in the most competitive specialties, nearly 1 in 3 qualified applicants walks away empty-handed according to The 10 Most Competitive Medical Residencies Report 2026. And the bar keeps rising. https://www.medscape.com/viewarticle/getting-medical-residency-harder-than-ever-heres-why-2026a1000jw0?ecd=wnl_edit_tpal_etid8422209&uac=148436CN&impID=8422209 Multidisciplinary Teams Could Ease Australia’s Urgent Care Workforce Concerns John Adie, MB, ChB, PhD For Australia’s healthcare system to be sustainable, as much care as possible must be moved from secondary care to primary care, and from primary care to nursing, paramedicine, and allied health professionals. This practical realization comes from my training, specialization, and work in New Zealand’s integrated primary care clinic (IPCC) and urgent care clinic (UCC) models as well as in Australian rural and remote medicine models. In these models, many patients with non-life-threatening urgent conditions are managed in community settings by multidisciplinary teams at a lower cost and less wait than if they were managed in hospital emergency departments. https://www.medscape.com/viewarticle/multidisciplinary-teams-could-ease-australias-urgent-care-2026a1000ix9?ecd=wnl_edit_tpal_etid8422209&uac=148436CN&impID=8422209 Chemo-Free Therapy in Pediatric Acute Promyelocytic Leukemia Cristina Ferrario STOCKHOLM —Eliminating anthracyclines from the treatment regimen of children and adolescents newly diagnosed with acute promyelocytic leukemia (APL) is feasible and yields excellent positive outcomes in standard-risk and high-risk patients, new data suggest. At the 2026 European Hematology Association Congress, Franco Locatelli presented the final results of the ICC-APL-02 trial, paving the way for a new treatment approach that dispenses with conventional chemotherapy in this pediatric population. https://www.medscape.com/viewarticle/chemo-free-therapy-pediatric-acute-promyelocytic-leukemia-2026a1000jvy?ecd=wnl_edit_tpal_etid8422209&uac=148436CN&impID=8422209 Fast Five Quiz: Melanoma Practice Essentials Reviewed by William James, MD; Maurie Markman, MD https://reference.medscape.com/viewarticle/fast-five-quiz-melanoma-practice-essentials-2025a1000e9k?ecd=wnl_edit_tpal_etid8422209&uac=148436CN&impID=8422209 Melanoma is an aggressive malignant tumor of melanocytes responsible for the vast majority of skin cancer-related mortality. Mastering practice essentials such as appropriate diagnostic biopsy technique, accurate assessment of Breslow thickness, evidence-based use of sentinel lymph node biopsy, and stage-appropriate imaging is critical to avoid understaging, optimize prognostication, and guide timely surgical and systemic management.

Optimizing the Transplant Experience: A Patient Journey Through Conditioning and GvHD Management Authors: Daniele Avenoso, MD, PhD; Filippo Milano, MD, PhD; Mareike Verbeek, MD; Robert Zeiser, MD

https://www.medscape.org/viewarticle/optimizing-transplant-experience-patient-journey-through-2026a1000bh8?page=1&src=mkmcmr_driv_stan_mscpedu_260613-OUS-HONC-optimizing-transplant-experience-patient-journey-through-2026a1000bh8-cta&uac=148436CN

RAS Drug Nearly Doubles Survival in Metastatic Pancreatic Cancer David Brzostowicki June 03, 2026

https://www.medscape.com/viewarticle/ras-drug-nearly-doubles-survival-metastatic-pancreatic-2026a1000ihe?ecd=mkm_ret_260614_mscpmrk_onc_mai_pancreatic-cancer_etid8418619&uac=148436CN&impID=8418619 An investigational oral drug that targets RAS, the dominant oncogenic driver in pancreatic cancer, nearly doubled overall survival compared with common second-line chemotherapy regimens in patients with previously treated metastatic disease.

Advancing Care in HER2-Mutated NSCLC: Evidence, Diagnostics, and Future Directions Authors: Balazs Halmos, MD, MS

https://www.medscape.org/viewarticle/advancing-care-her2-mutated-nsclc-evidence-diagnostics-and-2026a1000d6g?page=1&src=mkmcmr_driv_stan_mscpedu_260614-OUS-HONC-advancing-care-her2-mutated-nsclc-evidence-diagnostics-and-2026a1000d6g-cta&uac=148436CN

Navigating Advances in TRK Fusion-Positive Cancers: A Collaborative Journey From Testing to Therapy Authors: David S. Hong, MD; Theodore W. Laetsch, MD; Jonathan C. Trent, MD, PhD

https://www.medscape.org/viewarticle/navigating-advances-trk-fusion-positive-cancers-2025a1000z5i?page=1&src=mkmcmr_driv_stan_mscpedu_260612-OUS-HONC-navigating-advances-trk-fusion-positive-cancers-2025a1000z5i-cta&uac=148436CN

Drug-Induced Alopecia: When to Suspect and How to Treat It Matías A. Loewy

https://www.medscape.com/viewarticle/drug-induced-alopecia-when-suspect-and-how-treat-it-2026a1000jrt Key considerations in the diagnosis and management of drug-induced alopecia include the timing of onset, biologic plausibility, underlying pathophysiologic mechanism, and, in some cases, scalp biopsy findings, according to Jorge Larrondo Gálvez, MD , surgeon and specialist in dermatology and trichology in the Department of Dermatology, Clínica Alemana-Universidad del Desarrollo, Santiago, Chile.

Mesothelioma Survival Challenges Persist in the US Edited by Katie Lennon June 12, 2026

https://www.medscape.com/viewarticle/mesothelioma-survival-challenges-persist-us-2026a1000jsv Mesothelioma incidence and mortality declined more than 30% nationally from 1990 to 2023, with males experiencing reductions exceeding 40% while female rates decreased by < 10%. Female incidence increased in 20 states and mortality in 18, with occupational asbestos exposure accounting for more than 95% of deaths in 2023 and mortality-to-incidence ratios rising from 0.93 to 0.95.

Extrahepatic Cancer Risk Varies by Liver Disease Subgroups Edited by Vinod Rane, BS Pharm

https://www.medscape.com/viewarticle/extrahepatic-cancer-risk-varies-liver-disease-subgroups-2026a1000jlf Among subgroups of steatotic liver disease (SLD), metabolic dysfunction and alcohol-associated liver disease (MetALD) and alcohol-related liver disease (ALD) were associated with a higher risk for extrahepatic cancers than metabolic dysfunction-associated SLD (MASLD).

Chemo-Free Therapy in Pediatric Acute Promyelocytic Leukemia Cristina Ferrario Medscape Europe logo June 12, 2026

https://www.medscape.com/viewarticle/chemo-free-therapy-pediatric-acute-promyelocytic-leukemia-2026a1000jvy STOCKHOLM —Eliminating anthracyclines from the treatment regimen of children and adolescents newly diagnosed with acute promyelocytic leukemia (APL) is feasible and yields excellent positive outcomes in standard-risk and high-risk patients, new data suggest. At the 2026 European Hematology Association Congress, Franco Locatelli presented the final results of the ICC-APL-02 trial, paving the way for a new treatment approach that dispenses with conventional chemotherapy in this pediatric population. European Hematology Association (EHA) 2026 Congress https://www.medscape.com/c25/p14/european-hematology-association-eha-2026-congress-2026a1000g3s

Belzutifan Plus Pembro Approved for Adjuvant RCC M. Alexander Otto, PA, MMSc June 12, 2026

https://www.medscape.com/viewarticle/belzutifan-plus-pembro-approved-adjuvant-rcc-2026a1000jxb The FDA has approved belzutifan (Welireg, Merck) in combination with pembrolizumab (Keytruda, Merck) or the subcutaneous formulation of pembrolizumab (Keytruda Qlex, Merck) for the adjuvant treatment of adults with clear cell renal cell carcinoma.

Chronic Lymphocytic Leukemia: Data-Driven Updates in First-Line and R/R Disease Authors: Barbara F. Eichhorst, MD; Toby A. Eyre, MD, MBChB, DipMedEd, MRCP, FRCPath; Catherine Coombs, MD; Chan Cheah, MBBS, DMSc

https://www.medscape.org/viewarticle/chronic-lymphocytic-leukemia-data-driven-updates-first-line-2026a1000imb?page=1

Under the Skin: A Perspective on the Emerging Role of Intralesional Immunotherapy in Non-Melanoma Skin Cancer Authors: Nina Ran, MD, MS, MPH

https://www.medscape.org/viewarticle/under-skin-perspective-emerging-role-intralesional-2026a1000iwe?page=1&src=wnl_tpal_260612_mscpedu&uac=148436CN&impID=8419225

2026 NIST-University Research Summit June 30 - July 1, 2026 NIST 101 | Green Auditorium 100 Bureau Drive Gaithersburg, MD 20899

https://www.nist.gov/news-events/events/2026/06/2026-nist-university-research-summit Announcing our Keynote Speaker: Dr. Walter G. Copan We are honored to announce Dr. Walter G. Copan as the opening keynote speaker for the upcoming NIST-University Research Summit on June 30, 2026, at the NIST Gaithersburg, Maryland, campus. Dr. Copan currently serves as the Vice President for Research and Technology Transfer at the Colorado School of Mines, and is the co-founder and Senior Advisor of the Renewing American Innovation Project at the Center for Strategic and International Studies (CSIS). Dr. Copan will be returning to familiar ground, as he previously served as the Under Secretary of Commerce for Standards and Technology and the 16th Director of NIST. His distinguished career spans leadership roles across major corporations, entrepreneurial tech startups, U.S. government agencies, non-profits, and academia including impactful tenures at both Brookhaven National Laboratory and the National Renewable Energy Laboratory (NREL). Don’t miss this exclusive opportunity to gain insights from a visionary pioneer at the forefront of global innovation, technology commercialization, and energy policy. 📆 Dates: June 30 – July 1, 2026 📍 Location: NIST Gaithersburg Campus, 100 Bureau Drive, Gaithersburg, MD 20899

Steps for Personalized and Collaborative Decision-Making in HER2-Mutated NSCLC Authors: Pasi Jänne, MD, PhD, FASCO; Soo-Ryum (Stewart) Yang, MD; Xiuning Le, MD, PhD

https://www.medscape.org/viewarticle/steps-personalized-and-collaborative-decision-making-her2-2026a10007ur?page=1&src=mkmcmr_driv_stan_mscpedu_260612-OUS-HONC-steps-personalized-and-collaborative-decision-making-her2-2026a10007ur-cta&uac=148436CN

FDA approves capivasertib with abiraterone and prednisone for PTEN-deficient androgen pathway modulation-naïve or -sensitive prostate cancer

FDA approves capivasertib with abiraterone and prednisone for PTEN-deficient androgen pathway modulation-naïve or -sensitive prostate cancer https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-capivasertib-abiraterone-and-prednisone-pten-deficient-androgen-pathway-modulation On June 12, 2026, the Food and Drug Administration approved capivasertib (Truqap, AstraZeneca) in combination with abiraterone and prednisone for adults with metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S) prostate cancer (previously referred to as metastatic hormone-sensitive prostate cancer) that is PTEN-deficient as detected by an FDA-authorized test.

Decision-Making for Managing Myelofibrosis-Related Cytopenias: What Is Best Practice? Authors: Paola Guglielmelli, MD, PhD

https://www.medscape.org/viewarticle/decision-making-managing-myelofibrosis-related-cytopenias-2026a1000ar2?page=1&src=mkmcmr_driv_stan_mscpedu_260613-OUS-HONC-decision-making-managing-myelofibrosis-related-cytopenias-2026a1000ar2-cta&uac=148436CN Off-label therapies have not been approved for the use specified in this activity. This information should not be considered as a recommendation for the use of a drug outside of the recommendations in the currently approved Prescribing Information.

Missed Sexual Health Assessment May Limit Clinical Insight +++++ ++++

Clinical Insights Missed Sexual Health Assessment May Limit Clinical Insight Clinicians routinely assess physical activity, diet, and sleep when evaluating health; however, sexual life is rarely discussed. This overlooked dimension may offer meaningful insight into overall health status. Sexual activity is not only an intimate matter but also a reflection of an individual’s physical, mental, and social well-being. https://www.medscape.com/viewarticle/missed-sexual-health-assessment-may-limit-clinical-insight-2026a1000e4i?ecd=mkm_ret_260613_mscpmrk-OUS_InFocus_etid8417800&uac=148436CN&impID=8417800 Stroke Recovery May Miss a Key Dimension: Sexual Health https://www.medscape.com/viewarticle/stroke-recovery-may-miss-key-dimension-sexual-health-2026a10007vn?ecd=mkm_ret_260613_mscpmrk-OUS_InFocus_etid8417800&uac=148436CN& Stroke is the second leading cause of mortality worldwide and the third leading cause of disability-adjusted life-years lost. It is estimated that 1 in 6 people will experience a stroke during their lifetime. Most common long-term effects include speech impairment, difficulty with movement, and loss of functional independence. Diagnosing and Managing Erectile Dysfunction in Primary Care https://www.medscape.com/viewarticle/1003280?ecd=mkm_ret_260613_mscpmrk-OUS_InFocus_etid8417800&uac=148436CN&impID=8417800 In this episode, we're going to talk about the diagnosis and management of erectile dysfunction (ED) in primary care. The European Association of Urology updated its guideline on sexual and reproductive health during 2025, and I will focus on some of the key take-home messages from the ED section. ED is officially defined as the persistent inability to attain and maintain an erection sufficient to permit satisfactory sexual performance. And, as we all know, ED significantly affects psychosocial health and quality of life. STI Diagnoses Drop, but Syphilis in Women Rises https://www.medscape.com/viewarticle/sti-diagnoses-drop-syphilis-women-rises-2026a1000iqj?ecd=mkm_ret_260613_mscpmrk-OUS_InFocus_etid8417800&uac=148436CN&impID=8417800 Diagnoses of sexually transmitted infections (STIs) in England fell 8.3% in 2025, new data from the UK Health Security Agency (UKHSA) show — though rising syphilis rates in heterosexual women and growing antibiotic resistance are tempering the improvement. Sexual Dysfunction in Digestive Diseases Often Missed https://www.medscape.com/viewarticle/sexual-dysfunction-digestive-diseases-often-missed-2026a1000cry?ecd=mkm_ret_260613_mscpmrk-OUS_InFocus_etid8417800&uac=148436CN&impID=8417800 Digestive diseases, including anorectal cancers and functional gastrointestinal disorders, have a large and often underrecognized impact on sexual health, according to presentations at the Francophone Days of Hepatology, Gastroenterology, and Digestive Oncology 2026, held in Paris. HIV Transmission & Prevention HIV Patients in Senegal Skip Treatment Amid LGBTQ Arrests https://www.medscape.com/s/viewarticle/hiv-patients-senegal-skip-treatment-fearing-arrest-amid-anti-2026a1000dp1?ecd=mkm_ret_260613_mscpmrk-OUS_InFocus_etid8417800&uac=148436CN&impID=8417800 DAKAR, April 29 (Reuters) - Fewer patients are visiting some HIV treatment centres in Senegal amid a wave of arrests targeting LGBTQ people, according to health officials and government data seen by Reuters, threatening the country's fight against the virus. Can GPs Help End HIV Transmission by 2030? https://www.medscape.com/viewarticle/can-gps-help-end-hiv-transmission-2030-2026a1000eqw?ecd=mkm_ret_260613_mscpmrk-OUS_InFocus_etid8417800&uac=148436CN&impID=8417800 Every 5 years, people aged 40-74 in England are invited for an NHS Health Check — a routine blood test to screen for conditions including heart disease, diabetes, and kidney disease. Andrew Hill thinks it is time to add one more test to the list. "Why not add HIV?" he said. Transition From Pediatric to Adult HIV Care: Smooth for All? https://www.medscape.com/viewarticle/transition-pediatric-adult-hiv-care-smooth-all-2026a1000frg?ecd=mkm_ret_260613_mscpmrk-OUS_InFocus_etid8417800&uac=148436CN&impID=8417800 More than 80% of youth living with HIV in South Carolina transitioned from pediatric to adult care, but fewer than half did so in a timely and sustained manner. Various individual and social factors were linked to the odds of transition. HIV Treatment May Move Beyond Daily Pills With Injectables https://www.medscape.com/viewarticle/hiv-treatment-may-move-beyond-daily-pills-injectables-2026a1000bu9?ecd=mkm_ret_260613_mscpmrk-OUS_InFocus_etid8417800&uac=148436CN&impID=8417800 Long-acting injectable antiretroviral therapy improves treatment outcomes in individuals with HIV type 1 (HIV 1) who face adherence challenges, thereby addressing a persistent barrier in routine clinical care.

Clinical characteristics and outcomes in the adult cystic fibrosis population in Europe from 2014 to 2024: analysis of the European Cystic Fibrosis Society Patient Registry Annalisa Orenti, PhDa,b ∙ Prof Kris De Boeck, MDc ∙ Prof Eitan Kerem, MDd ∙ Prof Pierre-Régis Burgel, PhDe,f ∙ Anna Zolin, PhDa ∙ Egil Bakkeheim, MD PhDg,h ∙ et al.

Clinical characteristics and outcomes in the adult cystic fibrosis population in Europe from 2014 to 2024: analysis of the European Cystic Fibrosis Society Patient Registry Annalisa Orenti, PhDa,b ∙ Prof Kris De Boeck, MDc ∙ Prof Eitan Kerem, MDd ∙ Prof Pierre-Régis Burgel, PhDe,f ∙ Anna Zolin, PhDa ∙ Egil Bakkeheim, MD PhDg,h ∙ et al. https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(26)00149-9/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_ecfs26&_hsenc=p2ANqtz-9_aA1TI8tIXTP3N60YLkOKMmw_N190W-KMaGL0xMcnP6MpeyrRGD0LDHkoOKp51Aasgsm1nXXAREAF4CgJNErL4guqZA&_hsmi=422207923&utm_content=422207923&utm_source=hs_email Beyond efficacy: registries, equity, and outcomes in the ETI era Jonathan H Raymenta ∙ Jennifer L Taylor https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(26)00189-X/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_ecfs26&_hsenc=p2ANqtz-9imJogHlzAMK4cji8S-sv9uurnOPX_MnoCoEf6xRC14V7y1om2juZbZcwu8IvmdkFuxAc3itKdj_CPtSWjMdPEIduQ-w&_hsmi=422207923&utm_content=422207923&utm_source=hs_email

National and subnational burden of disease attributable to risk factors in Italy, 1990–2023: a systematic analysis from the Global Burden of Disease Study 2023 GBD 2023 Italy Risk Factors Collaborators ++...

National and subnational burden of disease attributable to risk factors in Italy, 1990–2023: a systematic analysis from the Global Burden of Disease Study 2023 GBD 2023 Italy Risk Factors Collaborators https://www.thelancet.com/journals/lanpub/article/PIIS2468-2667(26)00048-4/fulltext?dgcid=hubspot_email_lancet-gbdalerts&utm_campaign=gbdalerts&utm_medium=email&_hsenc=p2ANqtz--yfyvxIrC4FHlnJiFTo3SIIPm107O1RIaDHonQIaUI_Qh1wqS8LX-VhOzhk3R1WI7EW5bR4lxA7qRUt7RL9pvX7cN-YQ&_hsmi=423546589&utm_content=423510151&utm_source=hs_email Editorial e268 An opportunity to confront multimorbidity The Lancet Public Health https://www.thelancet.com/journals/lanpub/issue/vol11no5/PIIS2468-2667(26)X2004-7

Global, regional, and national levels and trends in maternal mortality, progress towards the Sustainable Development Goals, and mortality from COVID-19 infection in pregnant women, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023 GBD 2023 Maternal Mortality Collaborators ++...

Global, regional, and national levels and trends in maternal mortality, progress towards the Sustainable Development Goals, and mortality from COVID-19 infection in pregnant women, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023 GBD 2023 Maternal Mortality Collaborators https://www.thelancet.com/journals/lanogw/article/PIIS3050-5038(26)00047-6/fulltext?dgcid=hubspot_email_lancet-gbdalerts&utm_campaign=gbdalerts&utm_medium=email&_hsenc=p2ANqtz--w-ArhBi60JxPEMlLnQEx2XycFv4pVu1WFVsF_xe9DUFguOFxfl6y2rx3rck8N3NYQyJie61IIg3PT36eug9VcBna6cA&_hsmi=423546589&utm_content=423510151&utm_source=hs_email Editorial e357 Women at the centre of vaccination success The Lancet Obstetrics, Gynaecology, & Women's Health https://www.thelancet.com/journals/lanogw/issue/vol2no5/PIIS3050-5038(26)X2004-0

Global burden of cancer in children and adolescents aged 0–19 years, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023 GBD 2023 Childhood Cancer Collaborators ++...

Global burden of cancer in children and adolescents aged 0–19 years, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023 GBD 2023 Childhood Cancer Collaborators https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00200-X/abstract?utm_campaign=gbdalerts&utm_medium=email&dgcid=hubspot_email_lancet-gbdalerts&_hsenc=p2ANqtz-8hGopqePCjfTuCZEV36_QlD1GxUuoSxIKfMxXI0sHzyq-RUQLiU-B6Y11cjJaNZ_8G6Kr_bFUYqwnKIRy7hgdeWrwYxw&_hsmi=423546589&utm_content=423510151&utm_source=hs_email Editorial p1303 Childhood cancer: progress, but not enough The Lancet https://www.thelancet.com/journals/lancet/issue/vol407no10536/PIIS0140-6736(26)X2011-6

Global burden of metabolic dysfunction-associated steatotic liver disease, 1990–2023, and projections to 2050: a systematic analysis for the Global Burden of Disease Study 2023 GBD 2023 MASLD Collaborators ++...

Global burden of metabolic dysfunction-associated steatotic liver disease, 1990–2023, and projections to 2050: a systematic analysis for the Global Burden of Disease Study 2023 GBD 2023 MASLD Collaborators https://www.thelancet.com/journals/langas/article/PIIS2468-1253(26)00011-7/abstract?utm_campaign=gbdalerts&utm_medium=email&dgcid=hubspot_email_lancet-gbdalerts&_hsenc=p2ANqtz--BccPj2PjA-nWY_M_CHf5_7oA9XO13TytZTAQYGaXKLYSkKhfMR4AvQoqC4VuOxANJ4Ej5PWHPHVGyP8fOaMjcwgN6qg&_hsmi=423546589&utm_content=423510151&utm_source=hs_email Editorial p437 Confronting the global burden of MASLD The Lancet Gastroenterology & Hepatology https://www.thelancet.com/journals/langas/issue/vol11no6/PIIS2468-1253(26)X2004-0

Global, regional, and national burden of meningitis, its risk factors, and aetiologies, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023 GBD 2023 Meningitis & Antimicrobial Resistance Collaborators ++...

Global, regional, and national burden of meningitis, its risk factors, and aetiologies, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023 GBD 2023 Meningitis & Antimicrobial Resistance Collaborators https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(26)00101-8/abstract?utm_campaign=gbdalerts&utm_medium=email&dgcid=hubspot_email_lancet-gbdalerts&_hsenc=p2ANqtz-8MN-a_QCHFgfp6d4NjS-Gn4hAXlx3FAjcaUsIodmWiil2zAad9UuQHZhrnJ4ZBeR_yvOfkX8BHKSN4hKC0Norf43HBLA&_hsmi=423546589&utm_content=423510151&utm_source=hs_email Editorial p433 Europe at a brain health crossroads The Lancet Neurology https://www.thelancet.com/journals/laneur/issue/vol25no5/PIIS1474-4422(26)X2003-8

Updated trends in the global prevalence and burden of mental disorders, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023 GBD 2023 Mental Disorder Collaborators ++...

Updated trends in the global prevalence and burden of mental disorders, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023 GBD 2023 Mental Disorder Collaborators https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00519-2/abstract?utm_campaign=gbdalerts&utm_medium=email&dgcid=hubspot_email_lancet-gbdalerts&_hsenc=p2ANqtz--ePhRYb2s_zxpkkbZUcZY3OnqG3rZW_UIiHZVjnjYFTED0TDL19xDA5EMwenul9e-gMkvIfnCoTGOIVNDERndr5wNeYQ&_hsmi=423546589&utm_content=423510151&utm_source=hs_email Editorial p1987 Transforming the humanitarian system The Lancet https://www.thelancet.com/journals/lancet/issue/vol407no10543/PIIS0140-6736(26)X2018-9

Global childhood cancer surveillance: too many left in the dark The Lancet Child & Adolescent Health ++... ++

Global childhood cancer surveillance: too many left in the dark The Lancet Child & Adolescent Health https://www.thelancet.com/journals/lanchi/article/PIIS2352-4642(26)00136-7/fulltext?dgcid=raven_jbs_etoc_email Jul 2026 Volume 10Number 7p469-540, e17-e22 https://www.thelancet.com/journals/lanchi/issue/vol10no7/PIIS2352-4642(26)X2005-3 Global variation in injury patterns, interventions, and post-operative outcomes for children and adolescents undergoing trauma laparotomy: an international cohort study Riaz Aziz, FFICMa ∙ Dr Michael F Bath, MRCSa Send email to mb2583@cam.ac.uk ∙ Sarah M Abdelmohsen, MDb ∙ Isaac Chukwu, FWACSc ∙ Raoof Saleh, FRCSd ∙ Eder Cáceres, PhDe ∙ et al. https://www.thelancet.com/journals/lanchi/article/PIIS2352-4642(26)00069-6/fulltext?dgcid=raven_jbs_etoc_feature_lanchi Effectiveness of nirsevimab immunisation after birth versus RSVpreF maternal vaccination in preventing RSV-related hospitalisations in infants: a population-based retrospective cohort study Zaba Valtuille, PhDa,† ∙ Inès Fafi, MDa,b,c,† ∙ Prof Florentia Kaguelidou, MD PhDb,d ∙ Corinne Levy, MDe,f,g ∙ Prof Robert Cohen, MD PhDe,f,g ∙ Prof Laurent Mandelbrot, MD PhDh,i ∙ et al. https://www.thelancet.com/journals/lanchi/article/PIIS2352-4642(26)00075-1/abstract?dgcid=raven_jbs_etoc_feature_lanchi

Challenging the Confines of Risk of Recurrence in High-Risk HR+/HER2- Early Breast Cancer Authors: Joyce A. O’Shaughnessy, MD; Priya Rastogi, MD; Seth Wander, MD, PhD

https://www.medscape.org/viewarticle/challenging-confines-risk-recurrence-high-risk-hr-her2-early-2026a1000bq3?page=1&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_260607-OUS-HONC-challenging-confines-risk-recurrence-high-risk-hr-her2-early-2026a1000bq3-cta

Advancing Personalized Care for Prostate Cancer: Patient-Centered Solutions for mHSPC and nmCRPC Authors: Alicia K. Morgans, MD, MPH, FASCO; Christian Gratzke, MD; Fred Saad, MD, FRCS, FCAHS; Tony Collier, BEM

https://www.medscape.org/viewarticle/advancing-personalized-care-prostate-cancer-patient-centered-2025a1000uyb?page=1&src=mkmcmr_driv_stan_mscpedu_260607-OUS-HONC-advancing-personalized-care-prostate-cancer-patient-centered-2025a1000uyb-cta&uac=148436CN

Researchers trigger sleep’s restorative effect in parts of the awake brain

Researchers trigger sleep’s restorative effect in parts of the awake brain NIH-funded study in animals offers new details about how the brain resets during sleep. https://www.nih.gov/news-events/news-releases/researchers-trigger-sleeps-restorative-effect-parts-awake-brain By inducing specific patterns of activity in small portions of the brain in awake mice, researchers supported by the National Institutes of Health (NIH) have triggered a recalibration of neural connections that normally only occurs during sleep. This new approach offset the effects of sleep deprivation in memory tasks and revealed features of sleep that are key to its restorative effect. U.S. Department of Health and Human Services NATIONAL INSTITUTES OF HEALTH NIH News National Institutes of Health For Immediate Release: Monday, June 8, 2026 CONTACT: NIH Office of Communications, RESEARCHERS TRIGGER SLEEP’S RESTORATIVE EFFECT IN PARTS OF THE AWAKE BRAIN NIH-funded study in animals offers new details about how the brain resets during sleep By inducing specific patterns of activity in small portions of the brain in awake mice, researchers supported by the National Institutes of Health (NIH) have triggered a recalibration of neural connections that normally only occurs during sleep. This new approach offset the effects of sleep deprivation in memory tasks and revealed features of sleep that are key to its restorative effect. “What we’re essentially doing is forcing sleep in a local region of the brain. While that part is solidifying memories and restoring learning capacity, other parts stay aware/vigilant and connected to environment,” said corresponding author Chiara Cirelli, M.D., Ph.D., a professor of psychiatry at the University of Wisconsin-Madison. “Dolphins do something similar, sleeping with only one brain hemisphere at a time.” Non-rapid eye movement (NREM) sleep, which makes up about 80% of sleep for adults, is when the junctions between neurons that make memories are evaluated. During this phase, the brain protects important connections for long-term storage, prunes those that are less necessary, and makes space for new ones. Cirelli and her colleagues previously showed that, when sleep-deprived, both rats and humans can exhibit local slow-wave brain activity — a hallmark of NREM sleep — while awake. These deprivation-induced dips into sleep-like activity may have been too sporadic and brief to be beneficial, but the findings raised questions about the possible effects of a longer, more systematic version of this activity. In the new research, the authors used a combination of light-pulsing implants and genetic modifications to induce rhythmic on-and-off activity in one side of the brains of sleep deprived mice for 30 minutes at a time, mimicking patterns that occur during NREM sleep. When mice subsequently slept, slow-wave activity was lower in the specific brain regions the authors had stimulated, indicating less need for sleep. Additional experiments suggested that this effect hinged not on the overall reduction in neuronal firing, which some scientists had suggested was critical to recover from wake-induced neuronal fatigue, but rather on the specific alternating on-and-off pattern of activity. The researchers explored potential benefits through a behavioral test of tactile memory, for which sleep is important. Sleep-deprived mice who received stimulation in motor and sensory regions on both sides of the brain performed similarly to those who were well rested. Sleep-deprived mice who did not receive stimulation performed significantly worse. In future studies, Cirelli aims to learn whether similar effects could be replicated in humans using less invasive, transcranial stimulation technology. “This research further decodes why we sleep and how we learn, which brings us a step closer to understanding how to better prevent and treat cognitive decline,” said Amy Bany Adams, Ph.D., acting director of the NIH’s National Institute of Neurological Disorders and Stroke (NINDS), which funded the research. About the National Institute of Neurological Disorders and Stroke (NINDS): NINDS is the nation’s leading funder of research on the brain and nervous system. The mission of NINDS is to seek fundamental knowledge about the brain and nervous system and to use that knowledge to reduce the burden of neurological disease. https://www.ninds.nih.gov. About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov. NIH...Turning Discovery into Health -- Registered, U.S. Patent and Trademark Office --- REFERENCES: Kort Driessen et al. Induction of cortical ON/OFF periods in awake mice fulfills sleep functions. Nature Neuroscience. 2026. DOI: 10.1038/s41593-026-02318-9 ### This NIH News Release is available online at:

Psychological well-being and associated factors among orthopedic surgery residents in the United States Kyla A. Petrie, Paul Gaschen, Trent A. Petrie Volume 3, Issue 2

https://www.academia.edu/journals/academia-mental-health-and-well-being/articles?source=journal-top-nav Introduction: Over the last decade, mental health concerns have increased for medical students and residents. Our goal was to add to the literature by examining U.S. orthopedic surgery residents’ (N = 179; women = 84; White = 126) psychological well-being and the demographic and program-related factors associated with it. https://www.academia.edu/2997-9196/3/2/10.20935/MHealthWellB8314 Materials and methods: Residents anonymously completed a cross-sectional, online survey from September 2024 through January 2025. They provided demographic information as well as program factors. We assessed psychological well-being via life satisfaction, measuring it through the Satisfaction with Life Scale (SWLS). Faculty support was measured through the Johns Hopkins Learning Environment Scale (JHLES). Results: Just over 25% of residents reported neutral or lower levels of life satisfaction. Higher levels of life satisfaction were significantly correlated with sleep satisfaction (r = 0.29, p < 0.001), sleeping 6 to 8 h per night (r = 0.23, p = 0.002), having an ongoing interest in orthopedics (r = 0.56, p < 0.001), and support from residency program faculty (r = 0.52, p < 0.001). Further, the residents’ postgraduate year in their program (F (4, 174) = 3.57, p = 0.009) and their relationship status (F (2, 176) = 5.89, p = 0.003) mattered in terms of their reported levels of life satisfaction. Postgraduate year (PGY)-1 and PGY-5 residents had significantly higher life satisfaction than PGY-2 residents. Married residents were the most satisfied with their lives. Conclusions: Although generally satisfied, residents’ well-being varied significantly based on several key factors. Residency training programs can take active measures to help improve their residents’ well-being and life satisfaction, which may improve their surgical performance.

AI-designed miniproteins unlock control of GPCR signaling Study demonstrates that computationally-designed miniproteins can modulate GPCR activity in native cellular environments, expanding access to a major drug target family. Written byBree Foster, PhD

https://www.drugdiscoverynews.com/ai-designed-miniproteins-unlock-control-of-gpcr-signaling-17208?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-8o7WUg7Idl3S1RjjWIyU6fsc1jkRuUpVuhQ043ikSWj46QYVUidvfFc5NTsICqQjyqvnqW11IdDLZUaaPFBpAcoUf0BQ&_hsmi=422305080&utm_content=422305080&utm_source=hs_email G-protein-coupled receptors (GPCRs) are the largest and most versatile of cell surface receptors, with a broad repertoire of ligands and functions. Around one-third of approved medicines act on these membrane proteins, targeting a wide range of diseases from allergic rhinitis to pain, hypertension, and schizophrenia.

Weekly Rundown: Once-weekly HIV pill clears Phase 3 trials ​Microbubble-based genetic medicines, pharma deals, trial misses, and more led the news this week. Written byDDN editorial team

https://www.drugdiscoverynews.com/weekly-rundown-once-weekly-hiv-pill-clears-phase-3-trials-17254 Gilead Sciences and Merck announced this week that their investigational once-weekly single-tablet HIV regimen, islatravir/lenacapavir, met its primary efficacy endpoint at week 48 in both the ISLEND-1 and ISLEND-2 Phase 3 trials. The combination pairs Merck's islatravir, a next-generation nucleoside analog that blocks HIV replication through multiple mechanisms including reverse transcriptase translocation inhibition, with Gilead's lenacapavir, a first-in-class capsid inhibitor that disrupts HIV at multiple stages of its lifecycle. In ISLEND-1, the once-weekly tablet was non-inferior to Biktarvy, Gilead's current daily standard-of-care regimen, in virologically suppressed patients. In ISLEND-2, it was non-inferior to a broad range of daily antiretroviral regimens. Safety was comparable across arms with no new concerns identified. Both companies plan to file the Phase 3 data with regulatory authorities globally. If approved, islatravir/lenacapavir would become the first long-acting oral HIV treatment taken once weekly, a meaningful shift in a field where daily dosing has long been the norm and where adherence remains one of the most persistent barriers to sustained viral suppression. – Andrea Corona

About the Learn More Breathe Better® program

https://www.nhlbi.nih.gov/node-general/about-learn-more-breathe-betterr-program https://www.nhlbi.nih.gov/BreatheBetter

Arthritis

https://www.niams.nih.gov/health-topics/arthritis

Post-Traumatic Stress Disorder

https://www.nimh.nih.gov/health/publications/post-traumatic-stress-disorder-ptsd It is natural to feel afraid during and after a traumatic situation. Fear is a part of the body’s “fight-or-flight” response, which helps us avoid or respond to potential danger. People may experience a range of reactions after trauma, and most will recover from their symptoms over time. Those who continue to experience symptoms may be diagnosed with post-traumatic stress disorder (PTSD)

Lessons From the Real World: Treating High Risk HR+/HER2- Breast Cancer According to the Latest Evidence Authors: Nadia Harbeck, MD, PhD; Stephen Johnston, MA, FRCP, PhD; Sara Tolaney, MD, PhD

https://www.medscape.org/viewarticle/lessons-real-world-treating-high-risk-hr-her2-breast-cancer-2026a1000bhd?page=1&uac=148436CN&src=mkmcmr_driv_il_mscpedu_260611-12221249_ES_HONC#transcript-download-es

When the Pieces Don’t All Fit: Could It Be a Mitochondrial Myopathy? Authors: Caterina Garone, MD, PhD; Nuria Muelas, MD, PhD; Michelangelo Mancuso, MD, PhD

https://www.medscape.org/viewarticle/when-pieces-dont-all-fit-could-it-be-mitochondrial-myopathy-2026a1000f5i?page=1&uac=148436CN&src=mkmcmr_driv_il_mscpedu_260611_12247653_#transcript-download-es

How Are ADCs Shaping the Future of Early Breast Cancer Care? Latest Insights and Emerging Strategies Authors: Nadia Harbeck, MD, PhD; Giuseppe Curigliano, MD, PhD

https://www.medscape.org/viewarticle/how-are-adcs-shaping-future-early-breast-cancer-care-latest-2025a1000yca?page=1&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_260611-OUS-HONC-how-are-adcs-shaping-future-early-breast-cancer-care-latest-2025a1000yca-cta

Precision Oncology in HER2-Mutated NSCLC: Strategies for Today and Tomorrow Authors: Yong Fang, MD; Hye Ryun Kim, MD, PhD; Hibiki Udagawa, MD, PhD

https://www.medscape.org/viewarticle/precision-oncology-her2-mutated-nsclc-strategies-today-and-2025a100105r?page=1&src=mkmcmr_driv_stan_mscpedu_260611-OUS-HONC-precision-oncology-her2-mutated-nsclc-strategies-today-and-2025a100105r-cta&uac=148436CN

Recommended CME For You ++++ ++++ ++

Think You Know IDH-Mutant Glioma? Test Your Clinical Expertise on the Latest Advances CME Think You Know IDH-Mutant Glioma? Test Your Clinical Expertise on the Latest Advances Authors: Patrick Y. Wen, MD https://www.medscape.org/viewarticle/think-you-know-idh-mutant-glioma-test-your-clinical-2025a1000bve?page=1&src=mkmcmr_driv_invit_mscpedu&uac=148436CN This activity includes discussion of therapeutic products that have not been approved by the US Food and Drug Administration, off-label uses of approved products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein. New Standards in Diffuse Lower-Grade Gliomas: Integrative Management From Surgery to Survivorship CME Highlights from the Annual Neurosurgical Conference: New Standards in Diffuse Lower-Grade Glioma Authors: Mitchel S. Berger, MD; Macarena de la Fuente, MD; Michael Lim, MD https://www.medscape.org/viewarticle/1002598?src=mkmcmr_driv_invit_mscpedu&uac=148436CN H3 K27M-Mutant Glioma: A 360° View of Science, Physician Insights, and Patient Perspectives CME H3 K27M-Mutant Glioma: A 360° View of Science, Physician Insights, and Patient Perspectives Authors: Stephen J. Bagley, MD, MSCE; Charles Eberhart, MD, PhD; Carl Koschmann, MD; Ashley L. Sumrall, MD, FACP, FASCO; Michelle Sherman https://www.medscape.org/viewarticle/h3-k27m-mutant-glioma-360-view-science-physician-insights-2025a1000gki?page=1&src=mkmcmr_driv_invit_mscpedu&uac=148436CN Highlights From the Annual Oncology Meeting: Clinical Integration of Therapeutic Innovations in Glioma CME Highlights From the Annual Oncology Meeting: Clinical Integration of Therapeutic Innovations in Glioma Authors: Matthias Preusser, MD; Manmeet S. Ahluwalia, MD, MBA, FASCO; L. Nicolas Gonzalez Castro, MD, PhD; Jeremy Pivor https://www.medscape.org/viewarticle/1002677?src=mkmcmr_driv_invit_mscpedu&uac=148436CN Optimizing Outcomes for Thyroid Cancer With NTRK Gene Fusions: Precision Care, Patient Impact CME Optimizing Outcomes for Thyroid Cancer With NTRK Gene Fusions: Precision Care, Patient Impact Authors: Jaume Capdevila, MD, PhD; Gary Bloom; Umberto Malapelle, PhD; Lori J. Wirth, MD https://www.medscape.org/viewarticle/1002660?src=mkmcmr_driv_invit_mscpedu&uac=148436CN Advanced Neuroendocrine Tumors: Integrating Emerging Targeted Therapies Into Patient Care CME Advanced Neuroendocrine Tumors: Integrating Emerging Targeted Therapies Into Patient Care Authors: Marianne Pavel, MD; Jaume Capdevila, MD, PhD; Rachel Riechelmann, MD, PhD; Simron Singh, MD, MPH, FRCPC https://www.medscape.org/viewarticle/1002665?src=mkmcmr_driv_invit_mscpedu&uac=148436CN Managing Patients With HR+/HER2- EBC: Assess Your Knowledge CME Managing Patients With HR+/HER2- EBC: Assess Your Knowledge Authors: Reshma Mahtani, DO https://www.medscape.org/viewarticle/managing-patients-hr-her2-ebc-assess-your-knowledge-2025a1000ier?page=1&src=mkmcmr_driv_invit_mscpedu&uac=148436CN Targeted Therapies for NSCLC: Where Are We Today? CME Targeted Therapies for NSCLC: Where Are We Today? Authors: Solange Peters, MD, PhD; Benjamin J. Solomon, MBBS, PhD https://www.medscape.org/viewarticle/1002896?src=mkmcmr_driv_invit_mscpedu&uac=148436CN PTEN Deficiency in Prostate Cancer: Biology, Prognosis, and Therapeutic Relevance CME PTEN Deficiency in Prostate Cancer: Biology, Prognosis, and Therapeutic Relevance Authors: Elena Castro, MD, PhD https://www.medscape.org/viewarticle/pten-deficiency-prostate-cancer-biology-prognosis-and-2025a1000rqh?page=1&src=mkmcmr_driv_invit_mscpedu&uac=148436CN NF-1 Associated Plexiform Neurofibromas in Adults: Which Patients Could Benefit From Emerging Systemic Therapies? CME NF1-Associated Plexiform Neurofibromas in Adults: Which Patients Could Benefit From Emerging Systemic Therapies? Authors: Andrea Gross, MD; João Passos, MD https://www.medscape.org/viewarticle/1003044?src=mkmcmr_driv_invit_mscpedu&uac=148436CN